Navigation Links
Sinobiopharma Announces Second Quarter 2010 Financial Results
Date:1/19/2010

NANTONG CITY, China, Jan. 19 /PRNewswire-Asia-FirstCall/ -- Sinobiopharma, Inc. (OTC Bulletin Board: SNBP, "Sinobiopharma" or the "Company"), a fully integrated and highly innovative biopharmaceutical company engaged in the research and development, manufacture and marketing of pharmaceutical products in China, today announced financial results for the second quarter ended November 30, 2009.

    Second Quarter 2010 Highlights
    -- Total revenue increased by 120% year over year to approximately $2.1
       million.
    -- Gross margin increased 182% year over year to approximately $1.7
       million, or 80% of sales.
    -- Net income increased $2.1 million from a net loss of approximately $1.0
       million in the second quarter of 2009 to net income of approximately
       $1.1 million in the second quarter of 2010.
    -- The Company scaled up of production and marketing to launch
       Sinobiopharma's new drug YiTai (perindopril).

"We achieved excellent revenue and net income growth in the second quarter," said Dr. Lequn Huang, Sinobiopharma's Chairman and CEO stated. "The strong growth is largely due to our increased marketing efforts and strong demand for our main product KuTai (cisatracurium besylate). KuTai is replacing older-generation muscle relaxants since it is uniquely differentiated by both its performance profile and its convenience. KuTai is the only muscle relaxant that can be stored at room temperature. We feel confident that KuTai will continue to gain market share."

    Second Quarter 2010 Results
    -- Sales increased 120% to $2,137,471 for the three months ended November
       30, 2009, from $971,173 for the three months that ended November 30,
       2008. The increase in sales was due largely to the continuing growth
'/>"/>
SOURCE Sinobiopharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Sinobiopharma Reports Financial Highlights for Six-Month Period Ending November 30, 2008
2. Sinobiopharma Signs Export Agreement With U.S. Pharmaceutical Supplier
3. Sinobiopharma, Inc. Appoints New Director of Marketing
4. Sinobiopharma Reports a 41% Increase in Revenues From Unaudited Financial Results for the 9 Month Period Ended February 28, 2009
5. Sinobiopharma Reports a 141% Increase in Revenues From Unaudited Financial Results for the 9 Month Period Ended February 28, 2009
6. Sinobiopharma Secures Rights to Seven Key Patents
7. Sinobiopharma Announces SFDA Approval of Anti-Hypertension Drug Perindopril
8. Sinobiopharma Updates on Progress; Projects Increases in Sales and Revenues In 2009
9. Sinobiopharma Applies For Two Chinese Patents For Cisatracurium Besylate
10. Emissary Capital Group Initiates Coverage on Sinobiopharma
11. Sinobiopharma Reports Highlights From Audited Financial Results for the Fiscal Year Ended May 31, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... 2014 Research and Markets has ... Pulp & Paper Industry Report 2014" report to ... Pulp & Paper Industry Report 2014 is a professional ... global enzyme for pulp & paper industry. ... including definitions, classifications, applications and industry chain structure. The ...
(Date:8/27/2014)... Beach County, Florida (PRWEB) August 27, 2014 ... Company Inc. (SCI) is announcing the creation of ... priority is to take the SCI’s philosophy of ... the company’s research and development actions are based ... , This new Scientific Advisory Board provides a ...
(Date:8/27/2014)... (PRWEB) August 27, 2014 Remcom announces ... with new features for the biomedical industry. ... enhanced Biological Thermal Sensor, exclusive to the Bio-Pro version ... version of XFdtd, developed to calculate the biological effects ... has been added to all versions to expand engineers’ ...
(Date:8/26/2014)... 2014  NeuroSigma, Inc., a Los Angeles ... technologies, today announced that it has filed a registration ... Exchange Commission relating to a proposed initial public offering ... be offered and the price range for the proposed ... LLC will act as the book-running manager for the ...
Breaking Biology Technology:Global Enzyme for Pulp & Paper Industry Report 2014 2New Sancilio & Company, Inc. Scientific Board 2New Sancilio & Company, Inc. Scientific Board 3Remcom Announces Enhanced Biological Thermal Sensor and Other Biomedical Features in XFdtd EM Simulation Software Update 2Remcom Announces Enhanced Biological Thermal Sensor and Other Biomedical Features in XFdtd EM Simulation Software Update 3
... nanotubessorted by centrifuge for lengthmaterials scientists at the ... made some of the most precise measurements yet ... nanotubes become transparent, conducting sheets. Their recent experiments* ... overly short, but uniform in length nanotubes for ...
... DIEGO, Oct. 15 Amylin Pharmaceuticals,Inc. (Nasdaq: AMLN ... third quarter of 2008 on Tuesday, October 21, 2008 ... President and Chief Executive,Officer, will lead the call. On ... the third quarter of 2008., The call will ...
... Reduction in Composite Events When Using Routine ... FFR Guidance in Multi-Vessel Disease, ... announced the launch of the PrimeWire(TM) Pressure,Guidewire, and the s5-FFR ... consoles in the U.S. The PrimeWire is Volcano,s newest pressure,guidewire, ...
Cached Biology Technology:Paperwork: Buckypapers clarify electrical, optical behavior of nanotubes 2Amylin Pharmaceuticals to Webcast Third Quarter Results 2Volcano Corporation Announces Launch of PrimeWire(TM) Pressure Guidewire and s5-FFR Option for Existing Fleet of s5 IVUS Consoles 2Volcano Corporation Announces Launch of PrimeWire(TM) Pressure Guidewire and s5-FFR Option for Existing Fleet of s5 IVUS Consoles 3Volcano Corporation Announces Launch of PrimeWire(TM) Pressure Guidewire and s5-FFR Option for Existing Fleet of s5 IVUS Consoles 4Volcano Corporation Announces Launch of PrimeWire(TM) Pressure Guidewire and s5-FFR Option for Existing Fleet of s5 IVUS Consoles 5
(Date:8/26/2014)... a protective tent over a colony of harmful ... especially difficult. Microorganisms protected in a biofilm pose ... resistance and recalcitrance to treatment, and biofilm-protected bacteria ... infections in humans and are 50 to 1,000 ... infections. , "In essence, we may have stumbled ...
(Date:8/26/2014)... increasing pressure from policymakers, consumers, and suppliers has ... beyond reducing the pollutants they emit from their ... companies must also assess environmental performance at every ... primary materials to the use and recycling of ... to the discipline known as life cycle engineering, ...
(Date:8/26/2014)... New Jersey Institute of Technology (NJIT), is helping to ... the pace for daily life. , Evolution has harmonized ... fundamental rhythms of life that include the cycle of ... change. The brain,s circadian clock controls hormone production related ... by experiences such as jet lag or night-shift work, ...
Breaking Biology News(10 mins):Breakthrough antibacterial approach could resolve serious skin infections 2Breakthrough antibacterial approach could resolve serious skin infections 3Yale journal explores advances in sustainable manufacturing 2Researching fundamental rhythms of life 2Researching fundamental rhythms of life 3
... in response to vibrations within the inner ear, could form ... way to do this could be with gene therapy that ... Emory University School of Medicine have shown that introducing a ... induce the formation of extra sensory hair cells. Their ...
... in infant rats demonstrates that the anti-epilepsy drug phenobarbital ... using the first-line drug to treat epilepsy in human ... posted online May 11, researchers at Georgetown University Medical ... to rat pups about a week old changed the ...
... findings show that embryonic stem cells unable to fully ... task: differentiation into specific cell types that give rise ... the body. Researchers from the Georgia Institute of ... required for proper embryonic stem cell differentiation to occur. ...
Cached Biology News:Gene therapy for hearing loss: Potential and limitations 2Study raises questions about use of anti-epilepsy drugs in newborns 2Study raises questions about use of anti-epilepsy drugs in newborns 3Successful stem cell differentiation requires DNA compaction, study finds 2Successful stem cell differentiation requires DNA compaction, study finds 3Successful stem cell differentiation requires DNA compaction, study finds 4
Human VASA Biotinylated Affinity Purified PAb...
Mouse Iduronate 2-Sulfatase Affinity Purified Polyclonal Ab Keywords: Sulfatases, Iduronate 2-Sulfatase, Mucopolysaccharidosis, Hunter Syndrome, Glycobiology Protein Family: Proteoglycan Regu...
[14C]Polyethylene glycol 4000, 9.25 MBq, 250 uCi. Aqueous solution containing 3% ethanol, sterilized. 370-740 MBq/g, 10-20 mCi/g.1.85 MBq/ml, 50 uCi/ml. Category: Radiochemicals &Radiation Safety, ...
An instrument that delivers an accurate and uniform amount of light energy to cells to photoactivate csiRNA products....
Biology Products: